Cellectar to Participate at the Oppenheimer Rare & Orphan Disease Summit on May 21, 2021
On May 14, 2021, Cellectar Biosciences (NASDAQ: CLRB) announced its participation in the Oppenheimer Rare & Orphan Disease Summit on May 21, 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
On May 14, 2021, Cellectar Biosciences (NASDAQ: CLRB) announced its participation in the Oppenheimer Rare & Orphan Disease Summit on May 21, 2021. The company will be available for one-on-one meetings and will host an on-demand presentation for registered participants. Cellectar is focused on developing cancer-targeted therapies using its proprietary Phospholipid Drug Conjugate™ delivery platform. The company’s product pipeline includes CLR 131 and other preclinical PDC programs aimed at enhancing treatment efficacy and safety for cancer patients.
Details
News Market Reaction – CLRB
The recorded move for CLRB in the trading session of this news was +3.20%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FLORHAM PARK, N.J., May 14, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the company will participate and be available for 1x1 meetings at the following upcoming conference:
| Oppenheimer Rare & Orphan Disease Summit | |
| Date: | May 21, 2021 |
| Time: | On demand presentation for registered participants |
| Available for 1x1 meetings | |
| Webcast: | To register, click on the link HERE |
A replay of the presentation will be available on the Events page of the company website.
About Cellectar Biosciences, Inc.
Cellectar Biosciences is focused on the discovery and development of drugs for the treatment of cancer. The company is developing proprietary drugs independently and through research and development collaborations. The company’s core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to develop PDCs that specifically target cancer cells, delivering improved efficacy and better safety as a result of fewer off-target effects. The company’s PDC platform possesses the potential for the discovery and development of the next-generation of cancer-targeting treatments, and it plans to develop PDCs independently and through research and development collaborations.
The company’s product pipeline includes CLR 131, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope) and proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets.
For more information, please visit www.cellectar.com or join the conversation by liking and following us on the company’s social media channels: Twitter, LinkedIn, and Facebook.
Contacts
Investors:
Monique Kosse
Managing Director
LifeSci Advisors
212-915-3820
monique@lifesciadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.